The focus of this proposal is the development of polyoxometalate-based agents to inhibit HIV-1, the causative agent in AIDS. There are 3 main specific aims in this program. First, methods for the synthesis, purification and characterization of key polyoxometalate drugs including two top candidates, Si2W18Nb6O778- (1) and (Fe)4(H2O)2(P2W15O56)216- (2) and polyoxometalates with covalently attached organic groups will be further developed. Compound 1 exhibits high activity against HIV-1 and no detectable toxicity in a variety of cell cultures and appears to be well tolerated in mammals. Compound 2, while less developed thus far than 1, looks equally promising. The attachment of organic groups to polyoxometalates may lead to hydrophobic complexes with higher levels of blood-brain barrier permeability, higher degrees of oral bioavailability (and in particular optimized g.i. transport), and even higher mammalian tolerance. Second, newly discovered anti-HIV active and nontoxic polyoxometalates that are also potent and selective inhibitors of HIV- protease will be further studied. The detailed binding domain and mechanism of action will be probed. Large polyoxometalates including 1 and 2 that can prevent viral entry and the binding/fusion of uninfected and HIV-infected lymphocytes will be further investigated. Assays have been developed that should provide an insight into the mechanism of binding/fusion of certain polyoxometalates. Third, the mechanism of action of 1 and 2 and other lead compounds will be probed by in vitro selection of polyoxometalate-resistant strains. These studies will provide a rationale for studying drug combinations that may be clinically useful.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI032903-06
Application #
2457750
Study Section
AIDS and Related Research Study Section 4 (ARRD)
Project Start
1992-05-01
Project End
1998-07-31
Budget Start
1997-08-01
Budget End
1998-07-31
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Emory University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Judd, D A; Nettles, J H; Nevins, N et al. (2001) Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. J Am Chem Soc 123:886-97
Barnard, D L; Hill, C L; Gage, T et al. (1997) Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res 34:27-37
Ni, L; Boudinot, F D; Boudinot, S G et al. (1994) Pharmacokinetics of antiviral polyoxometalates in rats. Antimicrob Agents Chemother 38:504-10
Kim, G S; Judd, D A; Hill, C L et al. (1994) Synthesis, characterization, and biological activity of a new potent class of anti-HIV agents, the peroxoniobium-substituted heteropolytungstates. J Med Chem 37:816-20
Schinazi, R F; Sijbesma, R; Srdanov, G et al. (1993) Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene. Antimicrob Agents Chemother 37:1707-10